|
|
|
|
Recommended
Immunization Schedule
Ages 7-18 Years
UNITED STATES • 2010
|
|
|
|
|
This schedule includes
recommendations in effect as of December 15, 2009. Any dose
not administered at the recommended age should be
administered at a subsequent visit, when indicated and
feasible. The use of a combination vaccine generally is
preferred over separate injections of its equivalent
component vaccines. Considerations should include provider
assessment, patient preference, and the potential for
adverse events. Providers should consult the relevant
Advisory Committee on Immunization Practices statement
for detailed recommendations. Clinically significant adverse
events that follow immunization should be reported to
Vaccine
Adverse Event Reporting System (VAERS) or by telephone,
800-822-7967.
|
|
|
|
|
| |
1. Tetanus and diphtheria toxoids and acellular pertussis
vaccine (Tdap). (Minimum age: 10 years for
Boostrix® and 11 years for ADACEL™)
- Administer at age 11 or 12 years for
those who have completed the recommended childhood DTP/DTaP
vaccination series and have not received a tetanus and
diphtheria toxoids vaccine (Td) booster dose.
- Persons aged 13-18 years who
have not received Tdap should receive a dose.
- A 5-year interval from the last Td
dose is encouraged when Tdap is used as a booster dose;
however, a shorter interval may be used if pertussis
immunity is needed.
2. Human
papillomavirus vaccine (HPV). (Minimum age: 9
years)
- Two HPV vaccines are licensed: a quadrivalent
vaccine (HPV4) for the prevention of cervical, vaginal
and vulvar cancers (in females) and genital warts (in
females and males), and a bivalent vaccine (HPV2) for
the prevention of cervical cancers in females.
- HPV vaccines are most effective for both males and
females when given before exposure to HPV through sexual
contact.
- HPV4 or HPV2 is recommended for the prevention of
cervical precancers and cancers in females.
- HPV4 is recommended for the prevention of cervical,
vaginal and vulvar precancers and cancers and genital
warts in females.
- Administer the first dose to females at age 11 or 12
years.
- Administer the second dose 1 to 2 months after the
first dose and the third dose 6 months after the first
dose (at least 24 weeks after the first dose).
Administer the series to females at age 13 through 18
years if not previously vaccinated.
- HPV4 may be administered in a 3-dose series to males
aged 9 through 18 years to reduce their likelihood of
acquiring genital warts.
3. Meningococcal
vaccine (MCV4).
- Administer MCV4 at age 11–12 years
and at age 13–18 years if not previously vaccinated.
- Administer to previously unvaccinated college
freshmen living in a dormitory.
- Administer MCV4 to children aged 2 through 10 years
with persistent complement component deficiency,
anatomic or functional asplenia, or certain other
conditions placing them at high risk.
- Administer to children previously vaccinated with
MCV4 or MPSV4 who remain at increased risk after 3 years
(if first dose administered at age 2 through 6 years) or
after 5 years (if first dose administered at age 7 years
or older). Persons whose only risk factor is living in
on-campus housing are not recommended to receive an
additional dose. See
MMWR 2009;58:1042-3.
4.
Influenza vaccine (seasonal).
- Administer annually to children aged 6 months
through 18 years.
- For healthy nonpregnant persons aged 7 through 18
years (i.e., those who do not have underlying medical
conditions that predispose them to influenza
complications), either LAIV or TIV may be used.
- Administer 2 doses (separated by at least 4 weeks)
to children aged younger than 9 years who are receiving
influenza vaccine for the first time or who were
vaccinated for the first time during the previous
influenza season but only received 1 dose.
- For recommendations for use of influenza A (H1N1)
2009 monovalent vaccine. See
MMWR 2009;58(No. RR-10)
5.
Pneumococcal polysaccharide vaccine (PPSV).
- Administer to children with certain underlying
medical conditions, including a cochlear
implant. A single revaccination should be administered
to children with functional or anatomic asplenia or
other immunocompromising condition after 5 years
(see
MMWR 1997;46[No. RR-8]).
6. Hepatitis A
vaccine (HepA).
- The 2 doses in the series should be
administered at least 6 months apart.
- HepA is recommended for children older than 23
months who live in areas where vaccination programs
target older children or who are at increased risk of
infection, or for whom immunity against hepatitis A is
desired.
7. Hepatitis B
vaccine (HepB).
- Administer the 3-dose series to those
who were not previously vaccinated.
- A 2-dose series of (separated by at
least 4 months) of adult formulation Recombivax HB® is
licensed for children aged 11–15 years.
8.
Inactivated poliovirus vaccine (IPV).
- The final dose in the series should be administered
on or after the fourth birthday and at least 6 months
following the previous dose.
- If both OPV and IPV were administered
as part of a series, a total of 4 doses should be
administered, regardless of the child’s current age.
9. Measles, mumps, and rubella vaccine
(MMR).
- If not previously vaccinated, administer 2 doses or
the second dose for those who have received only 1 dose,
with at least 28 days between doses.
10. Varicella vaccine.
- For persons aged 7-18 years without evidence
of immunity (see
MMWR 2007;56[No. RR-4]), administer 2 doses
if not previously vaccinated or the second dose if they
have received only 1 dose.
- For persons aged 7-12 years, the minimum
interval between doses is 3 months. However, if the
second dose was administered at least 28 days after the
first dose, it can be accepted as valid.
- For persons aged 13 years and older, the minimum
interval between doses is 28 days.
|
| |
|
|
This page
was last updated on
January 21, 2010 |
|
